Uncategorized
Spark Therapeutics reports $123.7 million net loss in 2016
Spark Therapeutics reported a net loss of $123.7 million, or $4.29 per share, in 2016 compared with a net loss of $47.8 million, or $2.10 per share, in 2015, according to a company press release.Revenue in 2016 was $20.2 million, all from an agreement with Pfizer, compared with 2015 revenue of $22.1 million, of which $20.2 million was from the Pfizer agreement.